Poolbeg Pharma PLC Announces Voluntary Delisting from OTCQB Market Jul 26, 2024 02:00AM
Poolbeg Pharma PLC Announces Change of Registered Address Jul 2, 2024 02:00AM
Poolbeg Pharma PLC Announces Result of AGM Jun 17, 2024 04:20AM
Poolbeg Pharma PLC Announces Annual Report & AGM Notice May 9, 2024 02:00AM
Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA May 1, 2024 02:00AM


Apr 30, 2024 02:02AM Poolbeg Pharma PLC Announces Appointment of Joint Broker
Apr 30, 2024 02:01AM Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate
Mar 20, 2024 03:00AM Poolbeg Pharma PLC Announces POLB 001 US Patent Update
Feb 22, 2024 02:00AM Poolbeg Pharma PLC Announces Director/PDMR Shareholding
Feb 19, 2024 09:15AM Poolbeg Pharma PLC Announces Director Share Purchase
Jan 17, 2024 02:00AM Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS
Dec 20, 2023 02:00AM Poolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis Update
Dec 11, 2023 02:00AM Poolbeg Pharma PLC Announces POLB 001 Data Presented at ASH
Nov 30, 2023 02:00AM Poolbeg Pharma PLC Announces Directorate Change
Nov 21, 2023 02:00AM Poolbeg Pharma PLC Announces Immunomodulator II Patent Granted in Japan
Nov 16, 2023 02:00AM Poolbeg Pharma PLC Announces POLB 001 LPS Trial Data to be Presented at IUIS
Nov 9, 2023 02:00AM Former Amryt Pharma Leadership Team join Poolbeg
Nov 3, 2023 03:00AM Poolbeg Pharma PLC Announces POLB 001 Data to be Presented at American Society of Hematology Annual Meeting
Nov 1, 2023 03:00AM Poolbeg Pharma PLC Announces POLB 001 Oncology Programme Update Meeting
Oct 17, 2023 02:00AM Poolbeg Partners with a Nasdaq-Listed Biopharma
Sep 29, 2023 02:00AM Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition
Dec 12, 2022 02:00AM Poolbeg Pharma PLC - POLB 001 LPS Human Challenge Trial Completed
Nov 29, 2022 02:00AM Poolbeg Pharma PLC Announces Influenza AI model build completed